AN UPTON-upon-Severn technology firm has developed a test which can tell people if they have antibodies in their system after contracting Covid-19.
Bio-Diagnostics’ test will help people know if they have already been exposed to the disease.
The company has been visited by West Worcestershire MP Harriett Baldwin who has been championing the company’s invention and has already shared it with the Government’s Test and Trace team.
She has urged the authorities to take a close look at the new product as the company prepares to market it both in the UK and abroad.
The MP and John Smith, Worcestershire County Council’s cabinet member responsible for public health, were given a tour of the company’s laboratories by Bio-Diagnostics’ managing director Simon Mico and saw the testing process first hand.
Ms Baldwin said: “I’ve been in close touch with the company as it developed this test and I have shared the details with a number of Ministers as we ramp up our country’s testing capability.
“I am keen to champion this locally developed test which could be a real game changer as more people return to offices and our children return to school.
“Simon is clearly very passionate about this opportunity to offer a test which will make life much easier for many people who have had the disease but don’t yet know it.
“The Government is continuously looking at ways to expand our capacity for testing people who may currently have Covid-19, but alongside that I hope it will look closely at products which identify if we have had the disease and may be immune, as we continue our fight against this new virus.”
Mr Mico added: “This is completely different technology to anything else, testing with very high accuracy whilst attaining results in three minutes, can really support the efforts we are all making to reduce the pandemic.
“As the antibodies we detect develop after PCR tests cannot be used, we could take a pressure off that system proportionate to the number of people the BioCard positively identified.
“Being both highly specific and sensitive, we can now attain a much better understanding of who has immunity, even for asymptomatic people.”